Medicus Pharma Unveils Capital Strategy Centered On Novel Cancer Pipeline
Medicus Pharma advances its Pfizer-partnered cancer asset and plans a $135 million SkinJect SPAC deal while reducing quarterly operating expenses.
Stocks · News reference
Medicus Pharma Non-Binding LOI Values SkinJect At ~$135M Pre-Money In SPAC Deal With Unnamed SPAC; Sees Closing In H1 2027
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Medicus Pharma Sees ‘Substantial Reduction’ In Operating Expenses In Coming Quarters; Q3 Opex $14.5M
Medicus Pharma Q3 Net Loss $15.2M vs $16.0M Prior; Cash $5.0M At Sept 30, Plus $8.1M Restricted
Medicus Pharma to Outline CD228V Co-Development Strategy as It Prioritizes Capital Allocation, While Pursuing Separate Public Listing for SkinJect and Seeking Partners to Develop Teverelix
Medicus Pharma to Present at BIO-Europe 2026
Medicus Pharma announced that its Chief Medical Officer will present the company's precision oncology focus at the BIO-Europe 2026 conference.
Medicus Pharma Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Medicus Pharma reported its financial results for the third quarter of 2026 and highlighted strategic progress, including a proposed SPAC business combination for its SkinJect and Teverelix programs.